

GILEAD SCIENCES INC
Form 8-K
October 04, 2004

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

September 30, 2004

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of
incorporation or organization)

0-19731
(Commission File Number)

94-3047598
(I.R.S. Employer
Identification No.)

333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA

(Address of principal executive offices)

94404

(Zip Code)

Edgar Filing: GILEAD SCIENCES INC - Form 8-K

(650) 574-3000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Section 8 OTHER EVENTS

Item 8.01 Other Events

On September 30, 2004, Gilead Sciences, Inc., a Delaware corporation, issued a joint press release with Genelabs Technologies, Inc. announcing that the companies have entered into a research collaboration and license agreement for the development of Genelabs novel Hepatitis C compounds. A copy of the press release is filed as Exhibit 99.1 to this report.

Section 9 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

| Exhibit Number | Description |
|----------------|--|
| 99.1 | Press Release, issued by Gilead Sciences, Inc. on September 30, 2004 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| | |
|-----------------------|--|
| | GILEAD SCIENCES, INC. |
| | (Registrant) |
| | |
| | /s/ John C. Martin |
| | John C. Martin President and Chief Executive Officer |
| | |
| Date: October 4, 2004 | |

Exhibit Index

| Exhibit Number | Description |
|-------------------|--|
| 99.1 | Press Release, issued by Gilead Sciences, Inc. on September 30, 2004 |